Diabetic wound (DW) is described as a severe and disabling complication of diabetes mellitus (DM), commonly marked by delayed healing and persistent inflammation. The abstract emphasizes a clinical gap: an absence of sufficiently reliable biomarkers and noninvasive, real-time methods to detect and monitor disease progression in DW. Addressing these limitations motivated the development of molecular imaging strategies capable of reporting pathophysiologic changes as they occur.
The authors developed an activatable fluorescent molecular probe termed LRX specifically for the selective detection of peroxynitrite (ONOO-). The probe is presented as an optical chemosensor component suitable for fluorescence-based imaging. The article frames LRX as a tailored molecular tool intended to respond selectively to ONOO- so that changes in nitro-oxidative signaling can be imaged noninvasively and in real time.
According to the abstract, systematic evaluations demonstrated that LRX exhibited:
These characteristics are presented as essential prerequisites for an in vivo imaging probe intended to monitor reactive species dynamics in disease models.
The study applied LRX in a diabetic wound mouse model to test its performance in a biologically relevant setting. MeSH indexing indicates use of animal disease models and specifically lists mice, including inbred C57BL strains, consistent with preclinical in vivo work. Using the probe in this model, the investigators were able to visualize and monitor changes in ONOO- levels directly in vivo over time.
The central result reported in the abstract is that LRX enabled dynamic imaging of ONOO- fluctuations in diabetic wound tissue in the mouse model. The authors conclude that LRX can act as a sensitive and practical platform for real-time imaging of ONOO- under diabetic pathological conditions. These visualizations are presented as evidence that the probe can detect pathophysiological alterations in nitro-oxidative stress associated with diabetic complications.
The authors position their work as contributing two primary advances:
By enabling temporal observation of ONOO- dynamics, LRX may help link molecular oxidative/nitrosative events to wound progression and inflammation in preclinical models.
The abstract summarizes design, selectivity, stability, biocompatibility, and in vivo imaging outcomes, but it does not report detailed experimental methods, quantitative performance metrics, imaging parameters, or statistical outcomes. Specifics such as synthesis steps for LRX, limits of detection, interference profiles against individual reactive species, dosing, administration route, imaging time points, or histologic correlation are not provided in the abstract and would require consulting the full text. The animal model details beyond MeSH indexing (for example, exact diabetic induction method, sample sizes, or time course) are likewise not reported here.
The authors declared no known competing financial interests or personal relationships that could have appeared to influence the work, as stated in the conflict of interest section.
Overall, the abstract reports the development and preclinical application of an activatable fluorescent probe, LRX, that selectively images peroxynitrite and enables real-time visualization of ONOO- dynamics in a diabetic wound mouse model, with reported chemical stability and favorable biocompatibility. For complete experimental detail, numerical results, and methodological specifics, the full article should be consulted.